Monopar Therapeutics Inc
🔔 Watch stock
Assessment
Our Rating
A journalistic assessment by our editorial team at the time of the deep dive — it rates the company, not the entry point. Not investment advice and not a solicitation to buy or sell.
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Why this colour
The substance holds up. As of March 31, 2026 there is $137.5 million of liquidity against $2.589 million of liabilities, no interest-bearing debt, no going-concern warning and a runway management itself puts at least through December 31, 2027 — measured against the $12.2 million outflow of 2025, that is years rather than quarters. What is open is an operating question, and it is the largest one available: the company has never earned revenue, and the entire outcome hangs on a single regulatory decision on ALXN1840 — a drug its previous owner discontinued and one that, if approved, triggers up to $94.0 million of milestone payments. Add a $35.0 million repurchase from an entity connected to the chief executive and a real share base 49 percent above the reported count. That is not a proven substance problem, but it is not proven quality either — hence yellow. The decision is yours.
What the thesis turns on
Assessment: Opportunities & Risks
Monopar Therapeutics is a case you can tell in two sentences. The balance sheet is that of a healthy company: $137.5 million of liquidity as of March 31, 2026, $2.6 million of liabilities, no interest burden, a 98 percent equity ratio and, since July 22, 2026, a live approval filing for a drug whose Phase 3 trial met its primary endpoint. The business is a bet: no revenue since inception, 22 employees, a $93.4 million accumulated deficit, and a lead asset licensed from the very corporation that abandoned it — with up to $94.0 million of milestones and 10 percent to 20 percent royalties still to come. The road here was paid for in shares: 3,520,427 after the August 12, 2024 reverse split became 9,985,338 fully counted. Not investment advice.
Trial evidence
The pivotal trial in 214 patients met its primary endpoint — three times greater copper mobilization than standard of care over 48 weeks (difference 2.18 micromoles per liter, p below 0.0001). That is precisely what makes Alexion's exit so hard to read: two Phase 2 mechanistic trials could show neither a net-negative copper balance nor a reduction in hepatic copper. The objection is still part of the review, not settled.
Balance sheet
As of March 31, 2026 there is $137.5 million of liquidity against $2.589 million of liabilities and no interest-bearing debt at all; the equity ratio stands at 98.0 percent. Management sees funding at least through December 31, 2027; measured against the $12.2 million operating cash outflow of 2025, the runway would run into double-digit years.
Dilution
The 6,699,062 reported shares as of March 31, 2026 sit alongside 1,843,303 pre-funded warrants at $0.001, 842,973 options and restricted stock units, and 600,000 plan shares registered on July 22, 2026 — 9,985,338 in total, or 49 percent more. Only a quarter of the 40.0 million authorized shares has been used.
License chain
The lead asset does not belong to Monopar. Outstanding are milestones of up to $94.0 million — 68 percent of total liquidity as of March 31, 2026 — plus tiered royalties of 10 percent to 20 percent of net sales, 35 percent to 45 percent of any sublicensing income and an assumed third-party payment for Europe. All of it is triggered by the same event the stock is betting on.
Governance
One day after the September 23, 2025 offering raised $135.0 million gross, Monopar spent $35.0 million on September 24, 2025 repurchasing 550,229 of its own shares from Tactic Pharma LLC — an entity in which chief executive Chandler D. Robinson is a minority owner and non-controlling managing member. Roughly $91.9 million stayed with the company; 27.6 percent of net proceeds flowed out.
Valuation
Roughly $736 million of market value ($109.87, data as of July 26, 2026; cross-checked against the filing price of July 16, 2026: $721 million) stands against $137.5 million of tangible funds and zero revenue. Counting the pre-funded warrants brings it to roughly $939 million, leaving about $800 million of paid-for expectation — 5.4 times book value.
Worth Noting
Hook: rank 23 of 28 U.S. hits in our in-house Moglen weekly ranking (as of July 25, 2026), relative strength rating 87. The list is recalculated daily, and its criteria are purely price-based (at least 15 percent over four trading days, at least $10 million in average daily dollar volume, relative strength rating of 70 or better).
Data cut-off: balance sheet and earnings figures from the SEC quarterly report 10-Q for March 31, 2026 (filed May 14, 2026) and the annual report 10-K for 2025 (March 27, 2026); every filing through July 22, 2026 reviewed. Price, scanner and valuation data as of July 26, 2026.
Possible confusion: ALXN1840 still carries the code of its former owner Alexion but has been licensed to Monopar since October 23, 2024. The compound is also called tiomolibdate choline or TMC and is not identical to the older development code WTX101 under which parts of the trial program were run.
All share counts are adjusted for the 1-for-5 reverse split of August 12, 2024; 17,601,827 shares were outstanding before the split and 3,520,427 immediately after.
Stock Watch
This analysis is as of August 26, 2026. Stock Watch will tell you what's changed at MNPR since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 50.10 $ to 123.80 $ · Last price: 102.70 $ (As of: September 17, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/18/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc MNPR | 0.6 | – | -2.4 | – | – | -100.0 | 54.1 |
| Vertex Pharmaceuticals Inc VRTX | 130.6 | 31.3 | 24.5 | 55.0 | 38.1 | 9.6 | 33.4 |
| Regeneron Pharmaceuticals Inc REGN | 82.0 | 19.9 | 13.1 | 44.5 | 20.7 | 1.0 | 35.5 |
| Moderna Inc MRNA | 62.7 | – | 4.6 | -66.0 | -131.1 | -39.2 | 532.3 |
| argenx NV ARGX | 61.9 | 38.1 | 34.2 | 59.1 | 32.0 | 89.6 | 30.9 |
| Revolution Medicines Inc RVMD | 40.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 338.3 |
| BeiGene, Ltd. ONC | 40.0 | 63.1 | 34.1 | 88.9 | 19.1 | 40.2 | 6.4 |
| Alnylam Pharmaceuticals Inc ALNY | 32.6 | 61.8 | 28.4 | 79.7 | 23.0 | 65.2 | -48.1 |
| Royalty Pharma Plc RPRX | 32.5 | 31.8 | 19.6 | 95.8 | 100.3 | 5.1 | 68.6 |
| Median of companies shown | 40.9 | 34.9 | 19.6 | 57.0 | 21.8 | 5.1 | 35.5 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -1 | -1 | -0.12 | -1 | 3 | 3 |
| 2017 | 0 | -17 | -17 | -1.59 | -3 | 10 | 10 |
| 2018 | 0 | -3 | -3 | -0.31 | -3 | 7 | 7 |
| 2019 | 0 | -4 | -4 | -0.39 | -3 | 13 | 13 |
| 2020 | 0 | -7 | -6 | -0.58 | -5 | 16 | 17 |
| 2021 | 0 | -9 | -9 | -0.73 | -7 | 19 | 21 |
| 2022 | 0 | -11 | -10 | -0.83 | -7 | 10 | 13 |
| 2023 | 0 | -9 | -8 | -0.58 | -8 | 6 | 7 |
| 2024 | 0 | -16 | -16 | -1.36 | -6 | 55 | 60 |
| 2025 | 0 | -17 | -14 | -1.85 | -12 | 138 | 141 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -1.63 | – | 0 | – | – | -2 | -2 |
| 2025: Q1 | -0.39 | – | 0 | – | – | -6 | -6 |
| 2025: Q2 | -0.37 | – | 0 | – | – | -1 | -1 |
| 2025: Q3 | -0.48 | – | 0 | – | – | -2 | -2 |
| 2025: Q4 | -0.78 | – | 0 | – | – | -3 | -3 |
| 2026: Q1 | -0.46 | – | 0 | – | – | -4 | -4 |
| 2026: Q2 | -0.62 | -67.60 | 0 | – | – | -3 | -3 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 12 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
- Above the 50- & 200-SMA
- Gary Antonacci: Dual Momentum (Stock Adaptation)
- High ADR (≥5%)
- Power Trend
- Richard Moglen: 1 Week Top Performers
- Stan Weinstein: Stage 3
Research
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -3.01 | -5.25 – -1.88 | 0 | -62.5% | 11 |
| 12/31/2027 | -1.98 | -5.30 – 7.11 | 28 | 34.1% | 8 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
In den sechs ausgewerteten Filings gibt es keinen wesentlichen KI-Bezug: kein KI-Produkt, keine KI-Umsatzquelle und kein operativer KI-Einsatz; die einzige Erwaehnung steht als Boilerplate im Cybersicherheits-Risikofaktor des Geschaeftsberichts 2025.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-05-14 · 10-Q 2025-11-13 · 10-Q 2025-08-12 · 10-Q 2025-05-13 · 10-K 2026-03-27 · 10-K 2025-03-31
Rated on July 26, 2026 · How the Rating Is Built
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years no data
- More than 10% revenue growth is expected for the coming year 0.0%
- Share count grows by less than 3% a year -16.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") no data
- Gross margin at 40% or higher and without meaningful erosion no data
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 140 m net cash
- Operating cash flow covers the profits of the last three years 11 m
- Return on capital at 15% or higher, or up versus two years ago -12.1%
- Insiders hold at least 10% or are net buyers 23.2%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
1/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% –
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% –
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -10.0%
- ROCE > 15% -12.1%
- Expected return > 10% –
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Rioux Patrice | Acting Chief Medical Officer | Sell | 1 | 111.26 | 111 |
| Aug 26, 2026 | Rioux Patrice | Acting Chief Medical Officer | Other | 1,380 | 0.005 | 7 |
| Aug 26, 2026 | Tsuchimoto Kim R | Director | Sell | 590 | 113.84 | 67,166 |
| Aug 26, 2026 | Tsuchimoto Kim R | Director | Sell | 602 | 112.93 | 67,984 |
| Aug 26, 2026 | Tsuchimoto Kim R | Director | Sell | 1,098 | 111.84 | 122,800 |
| Aug 26, 2026 | Tsuchimoto Kim R | Director | Sell | 700 | 110.65 | 77,455 |
| Aug 26, 2026 | Tsuchimoto Kim R | Director | Sell | 615 | 109.56 | 67,379 |
| Aug 26, 2026 | Tsuchimoto Kim R | Director | Sell | 485 | 108.83 | 52,783 |
| Aug 25, 2026 | Anderson Raymond | Director | Sell | 1,802 | 113.05 | 203,716 |
| Aug 25, 2026 | Anderson Raymond | Director | Sell | 646 | 110.07 | 71,105 |
The company
About the Company
Monopar Therapeutics Inc., ein biopharmazeutisches Unternehmen in der klinischen Phase, befasst sich mit der Entwicklung von Therapeutika zur Krebsbehandlung in den USA.
- Employees
- 22
- Headquarters
- Wilmette, IL
- Address
- 1000 Skokie Boulevard, 60091 Wilmette, United States
- Phone
- 847 388 0349
- Website
- monopartx.com
- IPO Date
- 12/19/2019
- ISIN
- US61023L2079
- Stock Split
- 1:5 on 08/13/2024
Management
| Name | Title | Birth Year |
|---|---|---|
| Christopher M. Starr Ph.D. | Co-Founder & Independent Executive Chairman of the Board | 1952 |
| Chandler D. Robinson M.B.A., M.D., M.Sc. | Co-Founder, CEO, President & Director | 1984 |
| Quan Anh Vu | CFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer | 1972 |
| Andrew J. Cittadine M.B.A. | Chief Operating Officer | 1972 |
| Patrice P. Rioux M.D., Ph.D. | Acting Chief Medical Officer | 1951 |
| Susan Rodriguez | Chief Commercial & Strategy Officer | 1962 |
| Jeffrey D. Kent FACG, FACP, M.D. | Executive Vice President of Head of Medical Affairs | 1962 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.